DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.00
+0.78 (14.94%)
At close: Aug 13, 2025, 4:00 PM
5.77
-0.23 (-3.83%)
Pre-market: Aug 14, 2025, 9:02 AM EDT
DiaMedica Therapeutics Employees
As of December 31, 2024, DiaMedica Therapeutics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,056,429
Market Cap
310.13M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DMAC News
- 17 hours ago - DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia - Seeking Alpha
- 21 hours ago - DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - Business Wire
- 8 days ago - DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer - Business Wire
- 8 days ago - DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 - Business Wire
- 21 days ago - DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement - Business Wire
- 24 days ago - DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline - Business Wire
- 4 weeks ago - DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - Business Wire